Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 2/2020

01-04-2020 | Colon Cancer | Original paper

Long non-coding RNA LINC00858 exerts a tumor-promoting role in colon cancer via HNF4α and WNK2 regulation

Authors: Ting Xu, Kun Wu, Lei Zhang, Shutao Zheng, Xiaopeng Wang, Hao Zuo, Xu Wu, Guoquan Tao, Baofei Jiang, Li Zhang

Published in: Cellular Oncology | Issue 2/2020

Login to get access

Abstract

Background

Long non-coding RNAs (lncRNAs) are known to be frequently dysregulated in many types of human cancer. As yet, however, their roles in colon carcinogenesis have not been fully elucidated. In the current study, we assessed whether lncRNA LINC00858 may be involved in the progression of colon cancer and, in addition, investigated its downstream targets.

Methods

LINC00858 expression in patient-derived colon cancer tissues and in colon cancer cell lines was determined using RT-qPCR. Also, relationships between LINC00858 expression and various clinicopathological characteristics were analyzed. The subcellular localization of LINC00858 was determined using fluorescence in situ hybridization. Interactions between LINC00858 and its downstream targets were first predicted by bioinformatic analysis and, subsequently, confirmed by RNA pull-down, RNA immunoprecipitation, chromatin immunoprecipitation and dual luciferase reporter assays. After in vitro upregulation of LINC00858 and/or silencing of WNK2 and hepatocyte nuclear factor 4α (HNF4α), the biological behavior of colon cancer cells was assessed using 5-ethynyl-2′-deoxyuridine (EdU) incorporation, Transwell invasion and tube formation assays. In vivo cancer growth was evaluated in nude mice.

Results

We found that LINC00858 was highly expressed in primary colon cancer tissues and colon cancer cell lines, and was mainly located in the nucleus. High LINC00858 expression was found to correlate with a poor differentiation, advanced TNM stages and lymph node metastasis. Exogenous overexpression of LINC00858 promoted cell proliferation, invasion and migration of colon cancer cells, and facilitated angiogenesis and tumor growth. In addition, we found that LINC00858 can bind to and upregulate the nuclear transcription factor HNF4α, leading to WNK2 expression downregulation. This, in turn, resulted in the promotion of colon cancer cell growth.

Conclusions

From our data we conclude that LINC00858 acts as a tumor-promoting lncRNA in colon cancer by upregulating HNF4α and downregulating WNK2. Our results may provide novel targets for the treatment for colon cancer.
Literature
1.
M. Araghi, I. Soerjomataram, A. Bardot, J. Ferlay, C.J. Cabasag, D.S. Morrison, P. De, H. Tervonen, P.M. Walsh, O. Bucher, G. Engholm, C. Jackson, C. McClure, R.R. Woods, N. Saint-Jacques, E. Morgan, D. Ransom, V. Thursfield, B. Moller, S. Leonfellner, M.G. Guren, F. Bray, M. Arnold, Changes in colorectal cancer incidence in seven high-income countries: A population-based study. Lancet Gastroenterol. Hepatol. 4, 511–518 (2019)CrossRef
2.
M.P. Coleman, D. Forman, H. Bryant, J. Butler, B. Rachet, C. Maringe, U. Nur, E. Tracey, M. Coory, J. Hatcher, C.E. McGahan, D. Turner, L. Marrett, M.L. Gjerstorff, T.B. Johannesen, J. Adolfsson, M. Lambe, G. Lawrence, D. Meechan, E.J. Morris, R. Middleton, J. Steward, M.A. Richards, I.M.W. Group, Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377, 127–138 (2011)CrossRef
3.
F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018)CrossRef
4.
H. Deng, J.M. Wang, M. Li, R. Tang, K. Tang, Y. Su, Y. Hou, J. Zhang, Long non-coding RNAs: New biomarkers for prognosis and diagnosis of colon cancer. Tumour Biol. 39, 1010428317706332 (2017)PubMed
5.
M.L. Pecero, J. Salvador-Bofill, S. Molina-Pinelo, Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer. Cell. Oncol. 42, 1–12 (2019)
6.
C. Fang, S. Qiu, F. Sun, W. Li, Z. Wang, B. Yue, X. Wu, D. Yan, Long non-coding RNA HNF1A-AS1 mediated repression of miR-34a/SIRT1/p53 feedback loop promotes the metastatic progression of colon cancer by functioning as a competing endogenous RNA. Cancer Lett. 410, 50–62 (2017)CrossRef
7.
H.Y. Zhai, M.H. Sui, X. Yu, Z. Qu, J.C. Hu, H.Q. Sun, H.T. Zheng, K. Zhou, L.X. Jiang, Overexpression of long non-coding RNA TUG1 promotes Colon Cancer progression. Med. Sci. Monit. 22, 3281–3287 (2016)CrossRef
8.
S.P. Zhu, J.Y. Wang, X.G. Wang, J.P. Zhao, Long intergenic non-protein coding RNA 00858 functions as a competing endogenous RNA for miR-422a to facilitate the cell growth in non-small cell lung cancer. Aging (Albany NY) 9, 475–486 (2017)CrossRef
9.
Z. Gu, Z. Hou, L. Zheng, X. Wang, L. Wu, C. Zhang, Long noncoding RNA LINC00858 promotes osteosarcoma through regulating miR-139-CDK14 axis. Biochem. Biophys. Res. Commun. 503, 1134–1140 (2018)CrossRef
10.
Q.K. Sha, L. Chen, J.Z. Xi, H. Song, Long non-coding RNA LINC00858 promotes cells proliferation, migration and invasion by acting as a ceRNA of miR-22-3p in colorectal cancer. Artif. Cells Nanomed. Biotechnol. 47, 1057–1066 (2019)CrossRef
11.
D. Lin, Q. Huang, R. Wu, S. Dai, Z. Huang, L. Ren, S. Huang, Q. Chen, Long non-coding RNA AFAP1-AS1 promoting epithelial-mesenchymal transition of endometriosis is correlated with transcription factor ZEB1. Am. J. Reprod. Immunol. 81, e13074 (2019)CrossRef
12.
X. Gao, S. Zhao, X. Yang, S. Zang, X. Yuan, Long non-coding RNA FLVCR1-AS1 contributes to the proliferation and invasion of lung cancer by sponging miR-573 to upregulate the expression of E2F transcription factor 3. Biochem. Biophys. Res. Commun. 505, 931–938 (2018)CrossRef
13.
Q. Sun, W. Xu, S. Ji, Y. Qin, W. Liu, Q. Hu, Z. Zhang, M. Liu, X. Yu, X. Xu, Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Cancer Cell Int. 19, 49 (2019)CrossRef
14.
C. Walesky, U. Apte, Role of hepatocyte nuclear factor 4alpha (HNF4alpha) in cell proliferation and cancer. Gene Expr. 16, 101–108 (2015)CrossRef
15.
K. Chellappa, G.R. Robertson, F.M. Sladek, HNF4alpha: a new biomarker in colon cancer? Biomark. Med. 6, 297–300 (2012)
16.
L.Y. Lenertz, B.H. Lee, X. Min, B.E. Xu, K. Wedin, S. Earnest, E.J. Goldsmith, M.H. Cobb, Properties of WNK1 and implications for other family members. J. Biol. Chem. 280, 26653–26658 (2005)CrossRef
17.
C. Hong, K.S. Moorefield, P. Jun, K.D. Aldape, S. Kharbanda, H.S. Phillips, J.F. Costello, Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. Proc. Natl. Acad. Sci. U. S. A. 104, 10974–10979 (2007)CrossRef
18.
C. Dutruel, F. Bergmann, I. Rooman, M. Zucknick, D. Weichenhan, L. Geiselhart, T. Kaffenberger, P.S. Rachakonda, A. Bauer, N. Giese, C. Hong, H. Xie, J.F. Costello, J. Hoheisel, R. Kumar, M. Rehli, P. Schirmacher, J. Werner, C. Plass, O. Popanda, P. Schmezer, Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development. Oncogene 33, 3401–3410 (2014)CrossRef
19.
S. Moniz, F. Verissimo, P. Matos, R. Brazao, E. Silva, L. Kotelevets, E. Chastre, C. Gespach, P. Jordan, Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2. Oncogene 26, 6071–6081 (2007)CrossRef
20.
A.L. Hamilton SR, World Health Organization, International Agency for Research on Cancer. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press (2000).
21.
S.B. Edge, C.C. Compton, The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 17, 1471–1474 (2010)CrossRef
22.
Y. Li, Y. Jiao, J. Hao, H. Xing, C. Li, Long noncoding RNA TP73-AS1 accelerates the epithelial ovarian cancer via epigenetically repressing p21. Am. J. Transl. Res. 11, 2447–2454 (2019)PubMedPubMedCentral
23.
X. Fu, Y. Tian, W. Kuang, S. Wen, W. Guo, Long non-coding RNA DLX6-AS1 silencing inhibits malignant phenotypes of gastric cancer cells. Exp. Ther. Med. 17, 4715–4722 (2019)PubMedPubMedCentral
24.
A. Yamada, P. Yu, W. Lin, Y. Okugawa, C.R. Boland, A. Goel, A RNA-Sequencing approach for the identification of novel long non-coding RNA biomarkers in colorectal cancer. Sci. Rep. 8, 575 (2018)CrossRef
25.
M. Xue, D. Shi, G. Xu, W. Wang, The long noncoding RNA linc00858 promotes progress of lung cancer through miR-3182/MMP2 axis. Artif. Cells Nanomed. Biotechnol. 47, 2091–2097 (2019)CrossRef
26.
H. Yan, Q. Wang, Q. Shen, Z. Li, J. Tian, Q. Jiang, L. Gao, Identification of potential transcription factors, long noncoding RNAs, and microRNAs associated with hepatocellular carcinoma. J. Cancer Res. Ther. 14, S622–S627 (2018)CrossRef
27.
K. Chellappa, L. Jankova, J.M. Schnabl, S. Pan, Y. Brelivet, C.L. Fung, C. Chan, O.F. Dent, S.J. Clarke, G.R. Robertson, F.M. Sladek, Src tyrosine kinase phosphorylation of nuclear receptor HNF4alpha correlates with isoform-specific loss of HNF4alpha in human colon cancer. Proc. Natl. Acad. Sci. U. S. A. 109, 2302–2307 (2012)CrossRef
28.
F. Weltmeier, J. Borlak, A high resolution genome-wide scan of HNF4alpha recognition sites infers a regulatory gene network in colon cancer. PLoS One 6, e21667 (2011)CrossRef
29.
B. Fekry, A. Ribas-Latre, C. Baumgartner, J.R. Deans, C. Kwok, P. Patel, L. Fu, R. Berdeaux, K. Sun, M.G. Kolonin, S.H. Wang, S.H. Yoo, F.M. Sladek, K. Eckel-Mahan, Incompatibility of the circadian protein BMAL1 and HNF4alpha in hepatocellular carcinoma. Nat. Commun. 9, 4349 (2018)CrossRef
30.
H.S. Yao, J. Wang, X.P. Zhang, L.Z. Wang, Y. Wang, X.X. Li, K.Z. Jin, Z.Q. Hu, W.J. Wang, Hepatocyte nuclear factor 4alpha suppresses the aggravation of colon carcinoma. Mol. Carcinog. 55, 458–472 (2016)CrossRef
31.
Y.M. Yang, C.G. Lee, J.H. Koo, T.H. Kim, J.M. Lee, J. An, K.M. Kim, S.G. Kim, Galpha12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4alpha inactivation, which causes c-Met induction. Oncotarget 6, 19055–19069 (2015)PubMedPubMedCentral
32.
Z. Li, H. Chen, miR-34a inhibits proliferation, migration and invasion of paediatric neuroblastoma cells via targeting HNF4alpha. Artif. Cells Nanomed. Biotechnol. 47, 3072–3078 (2019)CrossRef
33.
L.M. Vuong, K. Chellappa, J.M. Dhahbi, J.R. Deans, B. Fang, E. Bolotin, N.V. Titova, N.P. Hoverter, S.R. Spindler, M.L. Waterman, F.M. Sladek, Differential Effects of Hepatocyte Nuclear Factor 4alpha Isoforms on Tumor Growth and T-Cell Factor 4/AP-1 Interactions in Human Colorectal Cancer Cells. Mol. Cell. Biol. 35, 3471–3490 (2015)CrossRef
34.
K. Chellappa, P. Deol, J.R. Evans, L.M. Vuong, G. Chen, N. Briancon, E. Bolotin, C. Lytle, M.G. Nair, F.M. Sladek, Opposing roles of nuclear receptor HNF4alpha isoforms in colitis and colitis-associated colon cancer. Elife 5 (2016)
35.
S. Moniz, O. Martinho, F. Pinto, B. Sousa, C. Loureiro, M.J. Oliveira, L.F. Moita, M. Honavar, C. Pinheiro, M. Pires, J.M. Lopes, C. Jones, J.F. Costello, J. Paredes, R.M. Reis, P. Jordan, Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness. Hum. Mol. Genet. 22, 84–95 (2013)CrossRef
36.
A.M. Costa, F. Pinto, O. Martinho, M.J. Oliveira, P. Jordan, R.M. Reis, Silencing of the tumor suppressor gene WNK2 is associated with upregulation of MMP2 and JNK in gliomas. Oncotarget 6, 1422–1434 (2015)PubMed
37.
L. Huang, X. Liu, microRNA-370 Promotes Cell Growth by Targeting WNK2 in Breast Cancer. DNA Cell Biol. 38, 501–509 (2019)CrossRef
38.
P. Jun, C. Hong, A. Lal, J.M. Wong, M.W. McDermott, A.W. Bollen, C. Plass, W.A. Held, D.J. Smiraglia, J.F. Costello, Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific. Neuro-Oncology 11, 414–422 (2009)CrossRef
39.
E.N. Gurzov, L. Bakiri, J.M. Alfaro, E.F. Wagner, M. Izquierdo, Targeting c-Jun and JunB proteins as potential anticancer cell therapy. Oncogene 27, 641–652 (2008)CrossRef
40.
C. Tam, J.H. Wong, S.K.W. Tsui, T. Zuo, T.F. Chan, T.B. Ng, LncRNAs with miRNAs in regulation of gastric, liver, and colorectal cancers: updates in recent years. Appl. Microbiol. Biotechnol. 103, 4649–4677 (2019)CrossRef
Metadata
Title
Long non-coding RNA LINC00858 exerts a tumor-promoting role in colon cancer via HNF4α and WNK2 regulation
Authors
Ting Xu
Kun Wu
Lei Zhang
Shutao Zheng
Xiaopeng Wang
Hao Zuo
Xu Wu
Guoquan Tao
Baofei Jiang
Li Zhang
Publication date
01-04-2020
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 2/2020
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-019-00490-8

Other articles of this Issue 2/2020

Cellular Oncology 2/2020 Go to the issue

Original paper

BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway

Review

HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer

Review

Esophageal carcinoma: Towards targeted therapies

Original paper

Mechanism of lung adenocarcinoma spine metastasis induced by CXCL17

Review

Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications

Original paper

The exosomal integrin α5β1/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits